Larimar Therapeutics, Inc. (LRMR) SEC Filings & Earnings Calls

Going concern uncertainty

“These conditions raise substantial doubt about our ability to continue as a going concern.” · word for word

Clinical trial risk (anaphylaxis)

“Ten participants experienced anaphylaxis and discontinued the study, including nine participants with prior nomlabofusp exposure.” · word for word

Dependence on regulatory approval

“If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties for our product candidates, we may generate revenue from those product candidates or collaborations.” · word for word

Clinical-stage biotech with no approved products; BLA approval not guaranteed.

“Approval will be a matter of review. Rolling BLA submission seeking accelerated approval underway.” · word for word

Anaphylaxis observed in 10 participants; safety monitoring required.

“Ten participants experienced anaphylaxis and discontinued the study; all responded to standard therapy.” · word for word

Regulatory and clinical risk for nomlabofusp BLA

“BLA submission pending FDA feedback; topline data expected Q2 2026; no approved product yet”

Cash burn rate

“Net loss $29.6M in Q1; cash runway into Q2 2027”

Clinical and regulatory risk

“We have not yet commercialized any products and do not expect to generate revenue from the commercial sale of any products for several years, if at all.” · word for word

Financing risk

“If we are required to obtain sufficient funding, but are unable to do so, when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs” · word for word

Cash burn risk

“Net cash used in operating activities $ (44,614 ) $ (26,540 )” · word for word

Regulatory and Clinical Risk for nomlabofusp

“If the first Performance Milestone set forth above is not achieved by December 31, 2026, then the full PSU award will be forfeited.” · word for word

Dilution Risk from Authorized Share Increase

“Proposal 5: Approval of an Amendment ... to Increase the Number of Authorized Shares of our Common Stock from 115,000,000 to 215,000,000.” · word for word

Clinical-stage biotech with no approved products; BLA submission and FDA approval are key risks.

“BLA seeking accelerated approval planned to be submitted in June 2026; U.S. launch targeted for first-half 2027, if approved.” · word for word

Clinical trial failure risk

“We cannot be certain that we will ultimately be successful with our clinical development or that we will ever be able to obtain regulatory approval for nomlabofusp.” · word for word

Capital need risk

“We may need to raise additional funding to complete the development and commercialization of nomlabofusp. This funding may not be available on acceptable terms, or at all.” · word for word

Safety/adverse event risk

“Anaphylaxis was reported in seven participants, with most events occurring on the initial day of administration and all occurring within the first 6 weeks of dosing.” · word for word

Dilution risk from convertible preferred stock exchange and increased authorized shares.

“Exchange of 2.5M common shares for 250K convertible preferred shares; authorized preferred increased from 250K to 500K.”

Preliminary unaudited data subject to change; no completed financial close.

“The Company has not yet completed its quarter-end or year-end financial close processes for the quarter and year ended December 31, 2025.” · word for word

Potential future dilution if preferred stock converted

“Each share of Preferred Stock convertible into 10 shares of Common Stock; conversion blocker at 9.99% can be increased to 19.99%”

Anaphylaxis safety signal

“In March 2025, we announced that our Safety Monitoring Team had identified anaphylaxis as an adverse drug reaction likely associated with nomlabofusp.” · word for word

Cash burn acceleration

“Net loss $ (47,712 ) (in thousands) for three months ended September 30, 2025 compared to $ (15,499 ) for three months ended September 30, 2024.”

Dependence on BLA approval

“We plan to submit a BLA seeking accelerated approval in the second quarter of 2026.” · word for word

No revenue and future dilution

“To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future.” · word for word

Anaphylaxis risk with nomlabofusp, particularly upon re-exposure, could impact patient enrollment and regulatory approval.

“7 of 65 participants experienced anaphylaxis; modified starting dose regimen implemented.”

Clinical-stage biotech with no approved products; regulatory and commercial risks remain high.

“Company is clinical-stage; BLA submission targeted for Q2 2026.”